Alkermes PLC (ALKS)

ALKS29.61 0.00%
  • O

    29.83

  • H

    30.25

  • L

    29.57

  • C

    29.61

  • V

    375k

Datos con 15 minutos de retraso

Términos comerciales

Horario comercial (UTC)
lunes: 11:00 - 00:00
martes - viernes: 00:00 - 00:30, 11:00 - 00:00
sábado: 00:00 - 00:30

Acerca

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

http://www.alkermes.com
х
Advertencia de riesgo: Invertir en mercados financieros contrae riesgos. El valor de la inversión puede tanto incrementar como disminuir y puede causar la perdida del capital del inversionista. En el caso de productos con apalancamiento, la pérdida puede ser mayor al capital invertido. Información detallada sobre los riesgos asociados con invertir en mercados financieros puede ser encontrada en divulgación completa de riesgos.
Póngase en contacto con nosotrosColapso